Gonzalo Sapisochin adresses the question of #livingdonor #livertransplant #LDLT for #HCC. As numbers of LDLT for HCC are growing - How do we select cancer patients that benefit most to justify living donor transplant? EASLnews #LiverCancerSummit

Living donor #livertransplantation reduced dropout of #HCC patients from the waiting list. So what is the ‘acceptable’ 5-year survival rate for #LDLT in #HCC? EASLnews #LiverCancerSummit

How do you manage #immunosuppression after #livertransplantation for #HCC? Massimo Iavarone summarizes the data on which immunosuppressants to choose EASLnews #LiverCancerSummit

How do you manage #HCC surveillance after #livertransplant for #HCC?

Massimo Iavarone proposes a decision tree for managing patients after #livertransplant for #HCC with high risk of recurrence EASLnews #livercancersummit

Davide Melisi presents data on the #FIGHT202 trial of #pemigatinib in #Cholangiocarcinoma targeting #FGFR mutations in #CCA. Over 1200 patients received #NGS profiling of #CCA, 146 patients were enrolled. EASLnews #LiverCancerSummit

Overall response rate to #pemigatinib in #cholangiocarcinoma in the FIGHT202 trial was 35% for patients carrying #FGFR fusion/rearrangements. Promising results that support further studies EASLnews #LiverCancerSummit Cholangiocarcinoma Foundation Global Cholangiocarcinoma Alliance

Peter Galle presenting data from #IMbrave150 trial of #Atezolizumab + #Bevacizumab in advanced #HCC for the Chinese subpopulation. OS and PFS as co-primary endpoints reflect the excellent global IMbrave 150 data EASLnews #LiverCancerSummit

Thanks to the organizers, the faculty, EASLnews and all delegates for makin this an outstanding #livercancersummit 2020! What a great, interactive, high quality meeting! See you at #ILC ILC

Next ⁦EASLnews⁩ destination! ⁦ILC⁩ #ILC2020

secure.avaaz.org/de/community_p…

#CoronaInfoCH #Coronavirus #soschützenwiruns Bitte teilen!

Immunotherapy may be less effective in #NASH-#HCC likely due to #NASH-related aberrant T cell activation. ⁦Wonderful work from Mathias Heikenwälder⁩ & colleagues. nature.com/articles/s4158…

Congrats and thanks to Mathias Heikenwälder and all other colleagues brining together this exciting paper on mechanisms of #immunotherapy in #NAFLD related #HCC. It's an honor to be part of this work. @nature EASLnews @BecherLab

Dringend: Die Schweiz muss jetzt den Menschen, die vor den #Taliban flüchten müssen, Schutz bieten! #AfghanistanIsNotSafe #Afghanistan #Kabul EDA - DFAE @EDA_DFAE_KOMM act.campax.org/petitions/huma…

So happy for this update that leaves behind all prior ones. Hope it will be a success because of wide recognition

Twitter is usually for professional topics. But today is a sad dat. War is such a failure for humanity. Nobody wins, the entire world loses. I hope and pray that all nations understand, and stop what is ongoing before it’s too late.

We, the #EASL Governing Board strongly condemn the invasion of #Ukraine 🇺🇦 by the Russian Federation! We call for #peace to protect civilians & prevent further harm. 🔁We call on fellow medical associations to join us. Read our statement of solidarity easl.eu/news/solidarit…

tagesanzeiger.ch/die-darmspiege…

Fertig mit Pressen - Sprechstunde Doktor Stutz doktorstutz.ch/fertig-mit-pre…